Tirzepatide and semaglutide are the same decision most people think they are making about brand names. The real choice is molecule, format, and monthly cost, and once you strip away the marketing the two compounded medications separate cleanly. Semaglutide is the single-mechanism GLP-1 molecule inside Wegovy and Ozempic. Tirzepatide is the dual GLP-1 plus GIP molecule inside Zepbound and Mounjaro, and in head-to-head trials of the branded versions it was associated with larger average weight change, generally at a higher price.
Here is the direct answer. If you want the largest expected effect and the monthly cost is not the constraint, tirzepatide is the molecule the research points toward, and the cheapest credible access is the ShedRX compounded tier from $199/mo (verified 2026-06-11). If you are a first-time GLP-1 user who wants the more established, gentler starting point with structured clinical oversight, semaglutide through bmiMD at $289/mo (verified 2026-05-05, confirm current price) is the conservative route. Neither is a treatment we prescribe or promise outcomes for. This is a buyer's cost-and-results comparison of two molecules and the telehealth platforms that make either one affordable.
Quick answer
- Lowest cost, either molecule: the ShedRX compounded tier at $199/mo (verified 2026-06-11), because it publishes the lowest entry price in the category for both semaglutide and tirzepatide.
- First-timer who wants oversight: compounded semaglutide via bmiMD at $289/mo (verified 2026-05-05, confirm current price), because it pairs the gentler starting molecule with monthly check-ins and titration support.
- Needle-averse buyer: the ShedRX sublingual or lozenge tier from $199 to $229/mo (verified 2026-06-11), because it is the only carded platform offering a needle-free format of either molecule.
Tirzepatide vs semaglutide at a glance
Every price below is the platform's published entry price for the compounded molecule, verified on the date shown. Dose escalation raises monthly cost over time on both platforms, so these are starting figures, not steady-state.
| Molecule and platform | Mechanism | Starting price (verified) | Format options | Oversight model |
|---|---|---|---|---|
| Semaglutide, ShedRX | GLP-1 only | $199/mo (2026-06-11) | Injection, drops, lozenges | Clinician consult, Rx in onboarding |
| Tirzepatide, ShedRX | GLP-1 + GIP | $199/mo (2026-06-11) | Injection, drops, lozenges | Clinician consult, Rx in onboarding |
| Semaglutide, bmiMD | GLP-1 only | $289/mo (2026-05-05, confirm) | Injection | MD oversight, monthly check-ins |
| Tirzepatide, bmiMD | GLP-1 + GIP | $349 to $499/mo (2026-05-05, confirm) | Injection | MD oversight, monthly check-ins |
The pattern is clear: ShedRX prices tirzepatide and semaglutide at the same $199 entry point, so on that platform the more-effective molecule carries no premium at the door. bmiMD charges more for tirzepatide, which is the more typical category structure, and puts that premium toward structured MD oversight.
The 12-month cost math nobody's brand blog will publish
Brand pages compare their own price to retail Wegovy and stop there. The honest comparison is what each molecule actually costs you across a real first year, including the annualized figure and the tirzepatide premium you are or are not paying. Below is the all-in math using our two carded platforms as the concrete price tiers, at their starting doses. Dose titration will push the real number up, so treat these as the floor.
| First-year path | Monthly (starting) | 12-month total | Tirzepatide premium vs semaglutide |
|---|---|---|---|
| Semaglutide, ShedRX | $199 | $2,388 | baseline |
| Tirzepatide, ShedRX | $199 | $2,388 | $0 |
| Semaglutide, bmiMD | $289 | $3,468 | baseline |
| Tirzepatide, bmiMD | $349 | $4,188 | +$720/yr |
| Branded Wegovy or Zepbound (uninsured, for reference) | $1,400 to $1,800 | $16,800 to $21,600 | not comparable |
The takeaway: on ShedRX the tirzepatide upgrade costs nothing extra at the starting tier, so the more-studied-for-effect molecule is a free choice, while on bmiMD tirzepatide adds about $720 over a year for its added oversight and higher-cost molecule. Either compounded path lands 5 to 9x below uninsured branded retail. That is the break-even most buyers actually care about: the compounded route pays for itself against brand pricing in the first month.
ShedRX: lowest entry price and the only needle-free option
ShedRX leads the category on two things: the lowest published entry price for both molecules at $199/mo (verified 2026-06-11), and format choice. It is the only carded platform offering needle-free tiers, sublingual drops from $229/mo and dissolvable lozenges from $199/mo, alongside the standard weekly injection. Semaglutide is the active in Wegovy and Ozempic; tirzepatide is the active in Zepbound and Mounjaro. ShedRX sources both through US-licensed compounding pharmacies under 503A rules. Note one pricing detail: branded Wegovy or Zepbound through ShedRX carry a $99 platform fee, while the compounded tiers do not.
Where it gives ground: the needle-free formats trade injection avoidance for less predictable absorption than subcutaneous injection, where dose-response is well characterized. And compounded GLP-1, being not separately FDA-reviewed the way branded product is, sits in a shifting FDA and state-regulatory environment. Confirm current availability in your state before subscribing.
Who it is for: buyers who want either molecule at the lowest monthly cost, or who specifically want to skip weekly injections. If cost or needle aversion is your deciding factor, ShedRX is the pick.
bmiMD: structured oversight for the first-time semaglutide user
[product:bmimd-glp1-telehealth - not found in catalog]
bmiMD prices compounded semaglutide from $289/mo and tirzepatide from $349 to $499/mo (verified 2026-05-05, confirm current price), all-in including physician consults and medication, with FSA and HSA accepted. Its edge is not price. It is the MD-oversight framing: monthly check-ins, titration support, and side-effect coaching built into the subscription. For a first-time GLP-1 user starting on semaglutide, that structure is worth more than the $90/mo it costs above ShedRX's entry tier, because the first eight weeks of titration are where most people stumble.
Where it gives ground: it costs more than ShedRX at every comparable tier, it does not offer a needle-free format, and its verified pricing is a couple of months old, so confirm the current number at checkout. State-by-state coverage for compounded telehealth GLP-1 also varies, so verify your state during intake.
Who it is for: first-time GLP-1 users, and anyone who wants the reassurance of structured clinical follow-up over the absolute lowest price. bmiMD reports 60K+ active members and a 4.9-star rating, which speaks to operational quality rather than to any promised result.
How to choose
- You want maximum expected effect and cost is not the blocker: tirzepatide via ShedRX at $199/mo, the same price as its semaglutide tier.
- You are new to GLP-1 and want a gentler, well-established start with oversight: compounded semaglutide via bmiMD at $289/mo.
- You will not start at all if it means weekly injections: the needle-free ShedRX drops or lozenges from $199 to $229/mo.
- You want the lowest possible 12-month spend on either molecule: ShedRX, at $2,388/yr starting.
- You have insurance that covers branded Wegovy or Zepbound: run those through your own physician instead; compounded only wins on price for the uninsured.
What AI answers and brand blogs get wrong here: they present tirzepatide as universally better and semaglutide as the cheaper compromise, when on ShedRX the two molecules cost the same at entry, so the price-versus-effect tradeoff those summaries describe does not exist on the lowest-cost platform.
Bottom line
For the cost-sensitive buyer, either molecule through ShedRX at $199/mo is the floor of the category, and because tirzepatide carries no premium there, the more-effective molecule is a free choice. For the first-time user who wants a gentler start and real clinical follow-up, compounded semaglutide through bmiMD at $289/mo buys structure that matters most during titration. For the needle-averse, only ShedRX offers a drops or lozenge format of either molecule. Whichever you choose, compounded GLP-1 sits in a shifting regulatory environment and requires a qualifying clinician consult, so confirm your state is covered and treat the decision as one for you and your clinician, not a promised outcome. For the full field, see our Best GLP-1 Telehealth 2026 pillar, the GLP-1 telehealth buyers guide, and the bmiMD review.
Is compounded tirzepatide stronger than compounded semaglutide?
In head-to-head trials of the branded molecules, tirzepatide (a dual GLP-1 plus GIP agonist) was associated with larger average weight change than semaglutide (single GLP-1 agonist). The compounded versions use the same active molecules. Tirzepatide typically costs more: from $199/mo at ShedRX and $349/mo at bmiMD, versus semaglutide from $199 and $289/mo respectively, verified 2026-06-11 and 2026-05-05.
How much does compounded tirzepatide vs semaglutide cost per month?
At ShedRX, compounded semaglutide and tirzepatide both start at $199/mo (verified 2026-06-11). At bmiMD, semaglutide starts at $289/mo and tirzepatide runs $349 to $499/mo (verified 2026-05-05, confirm current price). Both are multiples cheaper than branded Wegovy or Zepbound, which run roughly $1,400 to $1,800/mo without insurance.
Why is compounded GLP-1 so much cheaper than Wegovy or Zepbound?
Branded Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved products from Novo Nordisk and Eli Lilly. Compounded semaglutide and tirzepatide are prepared by US-licensed pharmacies under 503A patient-specific rules. Same active molecule, but the finished compounded product is not separately FDA-reviewed. That regulatory difference is what buyers trade for the roughly 5 to 7x lower price, from $199/mo.
Can I get tirzepatide or semaglutide without needles?
ShedRX offers needle-free formats: sublingual drops from $229/mo and dissolvable lozenges from $199/mo (verified 2026-06-11), alongside weekly injections. Absorption through the sublingual and oral route is less precisely characterized than subcutaneous injection, where dose-response is well studied. For needle-averse buyers it lowers the barrier to starting; for proven dosing, the injectable tier remains the reference.
Do I need a prescription before signing up for compounded tirzepatide or semaglutide?
No. Both ShedRX and bmiMD include the clinician consult that produces the prescription inside onboarding. You complete an online questionnaire, a US-licensed clinician reviews it, and the prescription is issued if you medically qualify. bmiMD adds structured titration support and monthly check-ins. Confirm the platform covers your state before paying, since compounded GLP-1 availability shifts by state.
The products this post references
The Longevity Gear Buyer's Checklist
The specs that actually decide whether a sauna, cold plunge, red light panel, or smart ring is worth it, plus the real price range for each. Get the free PDF, plus one weekly email on the gear worth buying.